CL2022000757A1 - Tienopirimidonas como inhibidores de trpa1 - Google Patents
Tienopirimidonas como inhibidores de trpa1Info
- Publication number
- CL2022000757A1 CL2022000757A1 CL2022000757A CL2022000757A CL2022000757A1 CL 2022000757 A1 CL2022000757 A1 CL 2022000757A1 CL 2022000757 A CL2022000757 A CL 2022000757A CL 2022000757 A CL2022000757 A CL 2022000757A CL 2022000757 A1 CL2022000757 A1 CL 2022000757A1
- Authority
- CL
- Chile
- Prior art keywords
- thienopyrimidones
- trpa1 inhibitors
- inhibitors
- diseases
- trpa1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención se refiere a tienopirimidinonas y a su uso como inhibidores de la actividad de TRPA1, a composiciones farmacéuticas que las contienen, y a métodos para usarlas como agentes para el tratamiento y/o la prevención de enfermedades fibróticas, enfermedades inflamatorias y autoinmunitarias y enfermedades relacionadas con el SNC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19203173 | 2019-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000757A1 true CL2022000757A1 (es) | 2023-01-20 |
Family
ID=68289874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000757A CL2022000757A1 (es) | 2019-10-15 | 2022-03-25 | Tienopirimidonas como inhibidores de trpa1 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20210107919A1 (es) |
| EP (1) | EP4045144A1 (es) |
| JP (1) | JP7354438B2 (es) |
| KR (1) | KR20220084127A (es) |
| CN (1) | CN114945408B (es) |
| AR (1) | AR120221A1 (es) |
| AU (1) | AU2020366678A1 (es) |
| BR (1) | BR112022003729A2 (es) |
| CA (1) | CA3153115A1 (es) |
| CL (1) | CL2022000757A1 (es) |
| IL (1) | IL292095A (es) |
| MX (1) | MX2022004564A (es) |
| PH (1) | PH12022550846A1 (es) |
| TW (1) | TW202128705A (es) |
| WO (1) | WO2021074197A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7612682B2 (ja) | 2019-10-15 | 2025-01-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なテトラゾール |
| TW202229292A (zh) * | 2020-10-14 | 2022-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為trpa1抑制劑之四唑衍生物 |
| IL301717A (en) * | 2020-10-14 | 2023-05-01 | Boehringer Ingelheim Int | Tetrazole history as TRPA1 inhibitors |
| AU2022257269A1 (en) | 2021-04-14 | 2023-08-17 | Boehringer Ingelheim International Gmbh | 3H,4H-THIENO[2,3-d]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| US8592398B2 (en) * | 2010-12-20 | 2013-11-26 | Glenmark Pharmaceuticals, S.A. | 2-amino-4-arylthiazole compounds as TRPA1 antagonists |
| RU2014100744A (ru) * | 2011-06-13 | 2015-07-20 | Гленмарк Фармасьютикалс С.А. | Лечение респираторных нарушений с помощью trpa1 антагонистов |
| JP6573968B2 (ja) | 2014-08-11 | 2019-09-11 | ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | ＴＲＰＣ５調節因子としての、精神神経障害の処置のためのチエノおよびフロ［２，３−ｄ］ピリミジン−２，４［１Ｈ，３Ｈ］−ジオン誘導体 |
| US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
| WO2016133888A1 (en) * | 2015-02-16 | 2016-08-25 | Biota Pharmaceuticals, Inc. | Compounds for treating respiratory syncytial virus infections |
| WO2017060488A1 (en) * | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
-
2020
- 2020-10-14 CA CA3153115A patent/CA3153115A1/en active Pending
- 2020-10-14 MX MX2022004564A patent/MX2022004564A/es unknown
- 2020-10-14 EP EP20789985.7A patent/EP4045144A1/en active Pending
- 2020-10-14 PH PH1/2022/550846A patent/PH12022550846A1/en unknown
- 2020-10-14 CN CN202080071930.XA patent/CN114945408B/zh active Active
- 2020-10-14 JP JP2022522350A patent/JP7354438B2/ja active Active
- 2020-10-14 BR BR112022003729A patent/BR112022003729A2/pt not_active Application Discontinuation
- 2020-10-14 KR KR1020227016330A patent/KR20220084127A/ko not_active Withdrawn
- 2020-10-14 AR ARP200102838A patent/AR120221A1/es not_active Application Discontinuation
- 2020-10-14 WO PCT/EP2020/078855 patent/WO2021074197A1/en not_active Ceased
- 2020-10-14 TW TW109135461A patent/TW202128705A/zh unknown
- 2020-10-14 AU AU2020366678A patent/AU2020366678A1/en not_active Abandoned
- 2020-10-15 US US17/071,092 patent/US20210107919A1/en not_active Abandoned
-
2021
- 2021-09-01 US US17/463,942 patent/US11578080B2/en active Active
-
2022
- 2022-03-25 CL CL2022000757A patent/CL2022000757A1/es unknown
- 2022-04-10 IL IL292095A patent/IL292095A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114945408A (zh) | 2022-08-26 |
| AR120221A1 (es) | 2022-02-02 |
| US20210107919A1 (en) | 2021-04-15 |
| KR20220084127A (ko) | 2022-06-21 |
| CN114945408B (zh) | 2024-04-16 |
| TW202128705A (zh) | 2021-08-01 |
| CA3153115A1 (en) | 2021-04-22 |
| PH12022550846A1 (en) | 2023-03-27 |
| US20210395267A1 (en) | 2021-12-23 |
| US11578080B2 (en) | 2023-02-14 |
| IL292095A (en) | 2022-06-01 |
| JP2022551956A (ja) | 2022-12-14 |
| MX2022004564A (es) | 2022-05-06 |
| EP4045144A1 (en) | 2022-08-24 |
| BR112022003729A2 (pt) | 2022-05-31 |
| JP7354438B2 (ja) | 2023-10-02 |
| WO2021074197A1 (en) | 2021-04-22 |
| AU2020366678A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000758A1 (es) | Tienopirimidonas como inhibidores de trpa1 | |
| CL2022000757A1 (es) | Tienopirimidonas como inhibidores de trpa1 | |
| MX2022006700A (es) | Compuestos poliheterociclicos como inhibidores de mettl3. | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| BR112019005595A2 (pt) | compostos e métodos para modulação de ido e tdo, e indicações para os mesmos | |
| CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| AR128259A2 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica | |
| CO2018003500A2 (es) | Anticuerpos anti-pd-1 y composiciones | |
| CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| MX388460B (es) | Composiciones de yodo. | |
| MX384213B (es) | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias. | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| MX387482B (es) | Derivados de n-cianopirrolidina de fórmula (i) con actividad como inhibidores de la peptidasa específica de ubiquitina (usp30). | |
| UY36215A (es) | Espirocicloheptanos como inhibidores de rock | |
| GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| CR20190394A (es) | Compuestos de inhibidores de autotaxina | |
| AR103895A1 (es) | Lactamas como inhibidores de rock | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| MX382624B (es) | Compuestos farmacéuticos. |